Effect of ω-3 Polyunsaturated Fatty Acids-Derived Bioactive Lipids on Metabolic Disorders

Jinjie Duan1,2†, Yayue Song1,2†, Xu Zhang1 and Chunjiong Wang1,2*

1 Department of Physiology and Pathophysiology, The Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Medical University, Tianjin, China, 2 Tianjin Key Laboratory of Medical Epigenetics, Tianjin Medical University, Tianjin, China

Arachidonic acid (ARA) is an important ω-6 polyunsaturated fatty acid (PUFA), and docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and n-3 docosapentaenoic acid (n-3 DPA) are three well-known ω-3 PUFAs. These fatty acids can be metabolized into a number of bioactive lipids. Eicosanoids derived from ARA have drawn great attention because of their important and complex biofunctions. Although EPA, DHA and n-3 DPA have also shown powerful biofunctions, we have fewer studies of metabolites derived from them than those from ARA. Recently, growing research has focused on the bioaction of ω-3 PUFA-derived metabolites, which indicates their great potential for treating metabolic disorders. Most of the functional studies of these bioactive lipids focused on their anti-inflammatory effects. However, several studies elucidated their direct effects on pancreatic β cells, hepatocytes, adipocytes, skeletal muscle cells, and endothelial cells. These researches revealed the importance of studying the functions of metabolites derived from ω-3 polyunsaturated fatty acids other than themselves. The current review summarizes research into the effects of ω-3 PUFA-derived oxylipins on metabolic disorders, including diabetes, non-alcoholic fatty liver disease, adipose tissue dysfunction, and atherosclerosis.

Keywords: ω-3 PUFA, eicosanoids, metabolic disorders, diabetes, NAFLD, adipose tissue, atherosclerosis

Abbreviations: ALA, α-linolenic acid; ARA, arachidonic acid; AMPK, AMP-activated protein kinase; BLT, leukotriene B4 receptor; cAMP, cyclic AMP; CCL, C-C motif chemokine ligand; COX, cyclooxygenase; CYP, cytochrome P450; DHA, docosahexaenoic acid; DHEA, docosahexaenoyl ethanolamine; DiHDPA, dihydroxydocosapentaenoic acid; DiHETE, dihydroxyeicosatetraenoic acid; DPA, docosapentaenoic acid; EDP, epoxydocosapentaenoic acid; EPA, eicosapentaenoic acid; EPEA, N-eicosapentaenoyl ethanolamine; ERV-1, Resolvin E1 Receptor; GPCR, G protein-coupled receptors; HDoHE, hydroxydocosahexaenoic acid; HEPE, hydroxyeicosapentaenoic acid; HFD, high-fat-diet; IFN-γ, interferon γ; IL, interleukin; LGR6, leucine-rich repeat containing G protein-coupled receptor 6; LOX, lipoxygenase; LXA4, lipoxin A4; MaR, maresin; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PD, Protocin; PDX, Protectin DX; PPAR, peroxisome proliferator-activated receptor; PUFA, polyunsaturated fatty acid; RvD, D-series resolvin; RvE, E-series resolvin; sEH, soluble epoxide hydrolase; TNF-α, tumor necrosis factor α; 7,17-DHDP, 17,17-dihydro-dipicolinic acid; 9-HOTRE, 9-hydroxy-octadecatrienoic acid; 13-(S)-HOTRE, 13-((S)-hydroperoxyoctadecatrienoic acid; 13-HPOTRE, 13-(S)-hydroperoxyoctadecatrienoic acid; 13-oxo-OTA, 13-Oxo-9(Z),11(E),15(Z)-octadecatrienoic acid; 14,15-DIHETRE, 14,15-dihydroxy-5,8,11-eicosatrienoic acid.
INTRODUCTION

Polyunsaturated fatty acids (PUFAs) refer to fatty acids with two or more double bonds in their backbone. Arachidonic acid (ARA) is an important ω-6 PUFA, which can be metabolized from linoleic acid (Schmitz and Ecker, 2008). Docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and n-3 docosapentaenoic acid (n-3 DPA) are three well-known ω-3 PUFAs and they can be derived from ω-linolenic acid (ALA). The estimated conversion rate of ALA to EPA was 8–20% in human, while that to DHA was 0.5–9%, even lesser (Stark et al., 2008). Those PUFAs are precursors of a series of bioactive lipids metabolized by cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450s (CYPs) and autoxidized non-enzymatically (Zhang et al., 2015).

Eicosanoids derived from ARA have drawn great attention because of their important and complex biofunctions. Many studies have examined the functions of ARA metabolites, including prostaglandins, thromboxanes, leukotrienes, lipoxins hydroxyeicosatetraenoic acids, and epoxyeicosatrienoic acid. These metabolites play vital roles in many physiological and pathophysiological processes. The effects of dietary supplement of ω-3 PUFAs are mediated not only by the precursor per se and their metabolites but also by competing the enzymes with ARA in the eicosanoid-producing process (Calder, 2020b). The effects of ARA and ARA-derived eicosanoids are well documented by several reviews (Sonnweber et al., 2018; Calder, 2020b). However, although ω-3 PUFAs also showed powerful biofunctions, we have fewer studies of their derived metabolites than those of ARA. Thus, we focused on the ω-3 PUFA derived bioactive lipids in the current review.

Metabolic disorders, such as obesity, diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease greatly threaten human health, and the prevalence of the diseases is increasing worldwide (Lavie et al., 2009; Younossi et al., 2016, 2018; Glovaci et al., 2019). In metabolic diseases, the profile of metabolites derived from ω-3 PUFAs is changed because of disturbed PUFA metabolism (Wang et al., 2017; Laguna-Fernandez et al., 2018; Garcia-Jaramillo et al., 2019). In the current review, we summarize the growing research into the effect of ω-3 PUFA-derived bioactive lipids on metabolic disorders, including diabetes, NAFLD, adipose tissue dysfunction and atherosclerosis.

THE METABOLIC PATHWAYS OF ALA, EPA, DHA, AND n-3 DPA

The metabolic pathways of ALA, EPA, DHA, and n-3 DPA were profoundly described by several reviews (Gabbs et al., 2015; Kuda, 2017; Drouin et al., 2019) and we briefly summarized as below:

ALA can be metabolized into hydroxy fatty acids by the COX and LOX pathway and epoxygenated fatty acids by the CYP pathway (Gabbs et al., 2015). In addition, ALA is the precursor of EPA, n-3 DPA and DHA. The rate limiting step is addition of a fourth double bond by Δ-6 desaturase. Next by elongation and desaturation, EPA is produced (Stark et al., 2008). EPA can be metabolized into 3-series prostaglandins and thromboxanes by the COX pathway; hydroxyeicosapentaenoic acids (HEPEs), E-series resolvins (RvE; RvE1-E3), 5-series leukotrienes and lipoxins by the LOX pathway; and epoxyeicosatrienoic acids (EETs) and dihydroxyeicosatetraenoic acids (dihETEs) by the CYP pathway (Zhang et al., 2015). Of note, 18-HEPE is derived from EPA by the CYP pathways or by aspirin-acetylated COX2 and then metabolized into RvEs by the LOX pathway (Figure 1; Gabbs et al., 2015).

Docosahexaenoic acid can be metabolized into hydroxydocosahexaenoic acids (HDHHEs), D-series resolvins (RvD; RvD1-D6), maresins (MaR; maresin 1 and 2), protectins (PD; PD1 and PDX) by the LOX pathway and epoxydocosapentaenoic acids (EDPs) and dihydroxydocosapentaenoic acids (DiHDPs) by the CYP pathway (Zhang et al., 2015). 17-hydroxydocosahexaenoic acid (17-H(p)DHA) is the precursor of DHA-derived specialized pro-resolving mediators. 17S-H(p)DHA can be metabolized from DHA by the LOX pathway and then metabolized into 17S-Hydroxy docosahexaenoic acid (17S-HDHA) and PD1. 17S-HDHA is further metabolized into RvDs and PDX. 17R-H(p)DHA is produced from DHA by aspirin-acetylated COX2 and then metabolized into 17R-HDHA and AT-PD1. 17R-HDHA can be further metabolized to AT-RvDs (Figure 1; Gabbs et al., 2015; Kuda, 2017).

n-3 DPA can be formed from EPA by elongase and converts to DHA by Δ6 or Δ4/-desaturase (Park et al., 2015; Drouin et al., 2019) thus it is an important intermediate in the conversion pathway of EPA and DHA (Figure 2). In addition, it can be metabolized into PDn3-DPA (PD1n3-DPA and PD2n3-DPA), RvDn3-DPA (RvD1n3-DPA, RvD2n3-DPA, and RvD5n3-DPA), MaRn3-DPA (MaR1n3-DPA, MaR2n3-DPA, and MaR3n3-DPA) and hydroxy-DPA through LOX pathway; 13-series Rvs though COX pathway and 13-oxo derivatives by COX pathway when aspirin is existed (Figure 2; Drouin et al., 2019).

As ARA, ω-3 PUFA can also generate oxylipins non-enzymatically, which is mediated by uncontrolled oxidation (Galano et al., 2015; Hajeyah et al., 2020). A LA generates phytoprostanes, EPA generates F3-isoprostanes and DHA generates F4-neuroprostanes and neurofurans non-enzymatically (Galano et al., 2015).

In addition to ω-3 PUFA-derived oxylipins, conjugates of ω-3 PUFA with ethanolamine form acylethanolamides, which belong to fatty acid amides. Ethanolamine conjugates of DHA and EPA termed docosahexaenoylethanolamine (DHEA) and N-eicosapentaenoylethanolamine (EPEA), respectively (Meijerink et al., 2013). DHEA and/or EPEA can also be further metabolized by COX, LOX and CYP pathway (de Bus et al., 2019). DHEA and EPEA showed anti-inflammatory effects (de Bus et al., 2019), which indicates they may have bioactive effects on metabolic disorders. Besides, ω-3 PUFA intake was reported to reduced endocannabinoid levels in plasma and various tissues (Saleh-Ghadimi et al., 2020).

In the present review, we focus on the oxylipins enzymatically derived from ω-3 PUFA.
Identifying the receptors of these lipid mediators is vital to investigate their functions and the underlying mechanisms. Several studies have revealed that the effects of metabolites derived from ω-3 PUFA are mediated by G protein-coupled receptors (GPCRs) or nuclear receptors (Table 1). Krishnamoorthy et al. (2010) reported that RvD1 can directly bind to two GPCRs, ALX, and GPR32. ALX was first identified as an LXA4 receptor and GPR32 was considered an orphan receptor. The authors further revealed that RvD1-stimulated phagocytosis in macrophages was mediated by ALX and GPR32 (Krishnamoorthy et al., 2010). GPR18 is identified as a RvD2 receptor (Chiang et al., 2015). The protective effects of PDX on oxidative stress in vascular endothelial cells were mediated by GPR120, thus GPR120 may be a putative receptor of PDX (Hwang et al., 2019). MaR1 derived from DHA specifically binds to and activates human leucine-rich repeat containing G protein-coupled receptor 6 (LGR6) (Chiang et al., 2019). RvE1 binds to leukotriene B4 receptor 1 (BLT-1) and ERV-1 (also known as ChemR23) (Freire et al., 2017). 5-HEPE is an agonist of GPR119, a GPCR that regulates insulin secretion in pancreatic β cells (Kogure et al., 2011).

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that can sense fatty acid and regulate lipid and glucose metabolism (Xu et al., 2018). The PPAR family includes three members, PPARα, PPARβ/δ, and PPARγ. HEPEs derived from EPA can activate PPARs (Yamada et al., 2014). 8-HEPE and 9-HEPE show higher ligand activities for PPARs than do 5-HEPE, 12-HEPE, 18-HEPE and EPA. Besides PPARs, MaR1 is an endogenous ligand of retinoic acid-related orphan receptor α (RORα) (Han et al., 2019). However, whether other ω-3 PUFA-derived metabolites are ligands of GPCRs or nuclear receptors is still unknown.

Type 1 diabetes is described as immune-mediated destruction of pancreatic β cells, and the characteristics of type 2 diabetes are insulin resistance and progressive β-cell failure (Yang et al., 2018). Diabetes is a major metabolic disorder with high prevalence and is a risk factor for relevant public health issues such as cardiovascular disease, retinopathy, microangiopathy, and impaired wound healing (Yang et al., 2018).

EPA and DHA have shown beneficial effects for both type 1 and type 2 diabetes in rodents (Krishna Mohan and Das, 2001; Suresh and Das, 2003; Bi et al., 2017; Lepretti et al., 2018) and there is increasing evidence that the metabolites of EPA and DHA regulate these procedures. However, clinical trials showed conflicting results of dietary supplement of EPA/DHA on metabolic parameters in diabetic patients. A 6-month EPA treatment decreased postprandial glucose level of newly diagnosed impaired glucose metabolism patients (Sawada et al., 2016). Another clinical research also revealed the beneficial effects of ω-3 PUFA supplement on metabolic parameters including glucose and glycosylated hemoglobin in type 2 diabetic patients (Jacobo-Cejudo et al., 2017). However, several clinical studies revealed neutral effects of ω-3 PUFAs on metabolic profiles in type 2 diabetic patients (Wong et al., 2010; Poreba et al., 2017). The disagreement of these studies may be related with different sample sizes, baseline characteristics of patients, different doses and purities of these fatty acid, different time courses of the treatments and different basic medicine of these patients. Moreover, Poreba et al. (2017) also demonstrated high-dose ω-3 PUFAs did not increase RvD1 level in patients with atherosclerosis and type 2 diabetes and this is an important clue that the production of bioactive metabolites of ω-3 PUFAs is related to their therapeutic effects (Poreba et al., 2017). Thus, to study the effects and mechanism of ω-3 PUFA-derived...
Recently, the bioactive lipids derived from EPA or DHA, including RvD1, RvD2, PDX, RvE1, and 5-HEPE, were reported to affect insulin resistance or pancreatic β-cell function (Table 2). Moreover, ω-3 PUFA metabolites can be involved in diabetic complications, including impaired wound healing and diabetic retinopathy (Table 2).

Effect of DHA-Derived Oxylipins on Diabetes

The levels of RvD1 and 17-HDHA were decreased in adipose tissue of genetic as well as diet-induced obese mice (Neuhofer et al., 2013). 17-HDHA treatment was further found to improve adipose tissue inflammation and insulin sensitivity in high-fat-diet (HFD)-fed mice (Neuhofer et al., 2013). Also, RvD1 has beneficial effects on insulin resistance. Hellmann et al. (2011) demonstrated that RvD1 improved glucose tolerance and increased insulin-stimulated pAkt level in liver, adipose tissue and skeletal muscle in db/db mice. The authors further found that RvD1 increased the ratio of M2 and M1 adipose-tissue macrophages (Bathina et al., 2020) and ameliorated adipose tissue inflammation (Hellmann et al., 2011). RvD1 was also reported to improve insulin resistance through the PI3K-Akt-mTOR axis in brain tissue (Bathina et al., 2020). In vitro study also indicated that RvD1 could attenuate interferon γ (IFN-γ)/lipopolysaccharide-induced pro-inflammatory cytokine expression in macrophages (Titos et al., 2011). Collectively, RvD1 improves insulin sensitivity by inhibiting tissue inflammation. Moreover, RvD1 ameliorated streptozotocin induced type1 diabetes in mice (Bathina and Das, 2021). In addition, local RvD1 delivery can accelerate...
### TABLE 2 | The functions of ω-3 PUFA-derived bioactive lipids on metabolic disorders.

| Metabolites          | Function                                      | Diseases                  | In vivo | In vitro | References                           |
|----------------------|-----------------------------------------------|---------------------------|---------|----------|--------------------------------------|
| **RvD1**             | – Insulin resistance;                         | Type 2 diabetes           | ✓       | ✓        | Hellmann et al., 2011; Bathina et al., 2020 |
|                      | – Adipose tissue Inflammation                 |                           |         |          |                                      |
|                      | – Oxidative stress                            | Type 1 diabetes           | ✓       |          | Bathina and Das, 2021               |
|                      | – Inflammation                                |                           |         |          |                                      |
|                      | + Healed of diabetic wounds                   | Diabetic complications    | ✓       | ✓        | Bathina and Das, 2021               |
|                      | – Pro-angiogenic potential of retinal photoreceptors |                           |         | ✓        | Maisto et al., 2020                 |
|                      | – NASH                                        |                           |         | ✓        |                                      |
|                      | – Macrophage inflammation                     | Obesity                   | ✓       | ✓        |                                      |
|                      | – Advanced atherosclerosis                    | Atherosclerosis           | ✓       |          | Fredman et al., 2016                |
| 17-HDHA, RvD1 precursor | – Adipose tissue Inflammation              | NAFLD                     | ✓       |           |                                      |
|                      | – Liver inflammation                          |                           |         |          |                                      |
| 17,18-EEQ            | – Insulin resistance (adipocyte)              | Obesity                   | ✓       |          |                                     |
| PD1                  | + Adiponecin secretion                        |                           |         |          |                                      |
| 19,20-DHDPA          | + Diabetic retinopathy                        | Diabetes                  | ✓       |          | Gonzalez-Periz et al., 2009          |
| 19,20-EDP            | + Autophagy (hepatocyte);                     | NAFLD; Obesity            | ✓       | ✓        | Lopez-Vicario et al., 2015           |
|                      | – Insulin resistance (adipocyte)              |                           |         | ✓        |                                      |
|                      | – Hepatic steatitis                           | NAFLD                     | ✓       | ✓        | Rius et al., 2017; Jung et al., 2018b; Laiglesia et al., 2018a |
|                      | + M2 polarity of liver macrophages            | NASH                      | ✓       | ✓        | Han et al., 2019                     |
| MaR1 + RvD2          | – Atherosclerosis;                             | Atherosclerosis           | ✓       | ✓        | Viola et al., 2016                   |
|                      | – Macrophage inflammatory                     |                           |         |          |                                      |
| PD1                  | + Adiponecin secretion                        | Obesity                   | ✓       |          | Gonzalez-Periz et al., 2009          |
| 19,20-DHDPA          | + Macrophage oxLDL uptake;                    | Atherosclerosis           | ✓       |          | Laguna-Fernandez et al., 2018        |
| 19,20-EDP            | – Atherosclerosis                             |                           |         |          |                                      |
| RvE1                 | – Hepatic steatitis                           | NAFLD                     | ✓       |          | Gonzalez-Periz et al., 2009          |
|                      | – Liver inflammation                          |                           |         |          |                                      |
|                      | – Atherosclerosis                             | Atherosclerosis           | ✓       |          | Salic et al., 2016                   |
|                      | – Insulin resistance;                         | Obesity                   | ✓       |          | Sima et al., 2017; Pal et al., 2020  |
|                      | – Inflammation                                |                           |         |          |                                      |
| RvE1 (RvE1 receptor overexpression) | – Insulin resistance (adipocyte) | Obesity                   | ✓       |          | Lopez-Vicario et al., 2015           |
|                      | – Macrophage oxLDL uptake;                    | Atherosclerosis           | ✓       |          |                                       |
|                      | – Atherosclerosis                             |                           |         |          |                                       |
| 18-HEPE/Resolvin E1 (RvE1 receptor deletion) | – NAFLD;                                     | NAFLD                     | ✓       |          | Rodriguez-Echevarria et al., 2018    |
|                      | – Macrophage oxLDL uptake;                    |                           |         |          |                                       |
| 18-HEPE              | – Atherosclerosis                             |                           |         |          |                                       |
| 8-HEPE               | – Dyslipidemia                                | NAFLD                     | ✓       |          | Saito et al., 2020                   |
| 17,18-EEQ            | – Insulin resistance (adipocyte)              | Obesity                   | ✓       |          | Lopez-Vicario et al., 2015           |
| 9-HEPE               | – Adipose tissue inflammation                 | NAFLD                     | ✓       |          | Wang et al., 2017                    |
| 5-HEPE               | – Macrophage inflammation                     |                           |         |          |                                       |
|                      | + T-reg in adipose tissue                     | Obesity                   | ✓       |          | Onodera et al., 2017                 |
|                      | + Insulin secretion                           | Diabetes                  | ✓       |          | Kogure et al., 2011                  |

(Continued)
wound closure in diabetic mice by stimulating macrophage phagocytosis to enhance clearance of apoptotic cells (Tang et al., 2013). In vitro study demonstrated RvD1 reduced the pro-angiogenic potential of retinal photoreceptors treated by high glucose by increasing anti-angiogenic miRNAs and decreasing VEGF content in exosomes (Maisto et al., 2020).

PDX-treated mice showed protection from lipid-induced insulin resistance. Along with this effect, PDX inhibited lipid-induced secretion of C-C motif chemokine ligand (CCL) 2, CCL5, tumor necrosis factor α (TNF-α), IFN-γ, interleukin 1β (IL-1β), IL-2, and IL-17. However, IL-6 level was significantly increased with PDX treatment, which was from skeletal muscle and suppressed gluconeogenic gene expression in liver (White et al., 2014). In addition, PDX can activate AMPK independent of IL-6 (White et al., 2014). Consistent with this finding, PDX improved HFD-induced insulin resistance in mouse skeletal muscle and palmitate-induced insulin resistance in skeletal muscle cells by activating AMPK and increasing PPARα expression (Jung et al., 2017). In hepatocyte, PDX ameliorated palmitate-induced insulin resistance by downregulating the expression of fetuin-A and selenoprotein P (Jung et al., 2019). Fetuin-A and selenoprotein P were hepatokines and their levels were increased in the plasma of obesity patients (Jung et al., 2019). PDX also improved lipopolysaccharide-induced insulin resistance in adipocytes (Jung et al., 2018a).

MaR1 treatment ameliorated insulin resistance in db/db mice and HFD-fed mice by suppressing inflammation and improving insulin sensitivity in adipose tissue (Martinez-Fernandez et al., 2017). The effects of MaR1 on insulin sensitivity were also confirmed in human adipocytes which were mediated by improving Akt activation (Martinez-Fernandez et al., 2020).

Soluble epoxide hydrolase (sEH) is a member of the epoxide hydrolase family in the CYP pathway (He et al., 2016). It hydrolyses EDPs into DiHDPAs. sEH expression and activity was found increased in retinas of diabetic mice, and the level of its product 19,20-DiHDPA was elevated in eyes. However, levels of other sEH substrates and products were comparable between control and diabetic mice. 19,20-DiHDPA was further found to increase endothelial cell permeability and induce the migration of pericytes into the extravascular space (Hu et al., 2017). Of note, the expression of sEH was increased in retinas of patients with non-proliferative diabetic retinopathy as compared with non-diabetic individuals (Hu et al., 2017), so sEH has potential as a therapeutic target of diabetic retinopathy.

### TABLE 2 | Continued

| Metabolites | Function | Diseases | In vivo | In vitro | References |
|-------------|----------|----------|---------|----------|------------|
| 12-HEPE     | + Cold adaptation; +Glucose uptake (adipocyte and skeletal muscle) | Diabetes | ✓ | ✓ | Leria et al., 2019 |
| RvD5-3DPA   | – Leukocyte and platelet activation – Aortic lesions | Atherosclerosis | ✓ | ✓ | Colas et al., 2018 |
| 13-oxo-OTA  | + Glucose uptake (adipocyte) | Diabetes | ✓ | ✓ | Takahashi et al., 2015 |

+, inhibit; +, promote; Ref., reference.

### Effect of EPA-Derived Oxylipins on Diabetes

BLT-1 and ERV-1 are two receptors for RvE1 (Freire et al., 2017). In type 2 diabetic patients’ neutrophils, ERV-1 expression was significantly upregulated and BLT-1 expression was decreased. In addition, the serum level of RvE1 was decreased in type 2 diabetic patients versus healthy controls. RvE1 was further found to facilitate neutrophil phagocytosis from healthy individuals, and a higher dose was needed to achieve a similar response in neutrophils of diabetic patients (Freire et al., 2017). These data indicate that repressed RvE1 signaling is involved in neutrophil phagocytosis dysfunction in type 2 diabetes. In addition, overexpression of the RvE1 receptor ERV-1 in myeloid cells attenuated diet-induced obesity, hepatic steatosis and glucose intolerance in mice. A mechanism study revealed that ERV-1 overexpression maintained peripheral blood monocyte and adipose-tissue macrophage skewing to an M2 phenotype in mice with an HFD (Sima et al., 2017). Besides, RvE1 was reported to improve hyperinsulinemia and hyperglycemia in HFD fed mice by activating ERV-1. The authors further demonstrated genetic diversity and variability defined the therapeutic effects of RvE1 by using the diversity outbred mice. This research highlights the genetic variants in the RvE1 response need to be considered when exploring the therapeutic effects of EPA clinically (Pal et al., 2020).

Eicosapentaenoic acid could increase glucose-stimulated insulin secretion from ob/ob mice (Neuman et al., 2017) 5-HEPE derived from EPA could increase glucose-stimulated insulin secretion in MIN6 cells by activating the GPR119/cAMP pathway (Kogure et al., 2011). Thus, the effect of EPA on insulin secretion may be mediated by its metabolites, which needs further investigation.

### Effect of ω-3 PUFA-Derived Oxylipins on Non-alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease is defined as the accumulation of excess fat in the liver in the absence of excessive alcohol drinking and any secondary cause and thus a hepatic manifestation of metabolic syndrome (Ahmed, 2015). In NAFLD, simple steatosis can progress into non-alcoholic steatohepatitis (NASH), estimated to be the major reason for liver transplantation in the United States by 2020 (Diehl and Day, 2017). EPA and DHA showed protective effects on NAFLD (Scorletti and Byrne, 2018;
Yan et al., 2018; Jordao Candido et al., 2019). Moreover, to better understand the underlying mechanisms, increasing studies have focused on the functions of their derived metabolites in NAFLD.

**Effect of ω-3 PUFA-Derived Oxylipins on Hepatic Steatosis**

Hepatic steatosis is considered the first hit in the current “multiple-hit” theory proposed for the pathogenesis of NAFLD (Ahmed, 2015). PDX, MaR1, 19,20-EDP, and 17-HDHA derived from DHA and 17,18-EEQ, 18-HEPE, and RvE1 derived from EPA showed potential to ameliorate hepatic steatosis (Table 2).

PDX and MaR1 suppress palmitate-induced lipid accumulation in hepatocytes by attenuating endoplasmic reticulum stress (Rius et al., 2017; Jung et al., 2018b,c). For the mechanism, MaR1 activated AMPK and then induced endoplasmic reticulum stress (Rius et al., 2017; Jung et al., 2018b,c). For the mechanism, RvD1 suppressed palmitate-induced endoplasmic reticulum stress (Jung et al., 2018b). Consistent with the in vitro study, in HFD-fed mice and ob/ob mice, MaR1 alleviated hepatic steatosis (Jung et al., 2018b; Laiglesia et al., 2018b). 18-HEPE and 17-HDHA could improve HFD-induced hepatic steatosis. Also, 18-HEPE and 17-HDHA increased adiponectin level in HFD mouse (Rodriguez-Echevarria et al., 2018). However, whether the beneficial effects of 18-HEPE and 17-HDHA depend on adiponectin need further studies. 18-HEPE is the precursor of 18-HDHA and 17-HDHA could improve HFD-induced hepatic steatosis. Also, 18-HEPE and 17-HDHA increased adiponectin level in HFD mouse. MaR1 alleviated hepatic steatosis and inflammation of ob/ob mice. For the mechanism, RvD1 alleviated hepatic steatosis and inflammation by promoting M2 polarization of liver macrophages. Also, Han et al. (2019) demonstrated that MaR1 derived from DHA increased the M2 polarity of liver macrophages and then ameliorated NASH by activating RORα. RORα, as a nuclear receptor, in turn increased MaR1 production by transcriptional induction of 12-lipoxygenase expression (Han et al., 2019). These studies suggest that these specialized pro-resolving lipid mediators derived from ω-3 PUFA have therapeutic potential for NASH by promoting M2 polarization of liver macrophages.

**EFFECT OF ω-3 PUFA-DERIVED OXYLIPINS ON ADIPOSE TISSUE FUNCTION**

Depending on the adipocyte, adipose tissue can be divided into white and brown adipose tissue. Also, inducible cells within white adipose tissue, called “beige” adipocytes, can generate heat under cold exposure (Rosen and Spiegelman, 2014; Ye et al., 2020). Adipose tissue functions, including adipose tissue inflammation, lipolysis, adipogenesis, endocrine function, and browning, are closely related to obesity-related diseases. The studies of the effects of ω-3 PUFA derivatives on adipose tissue function mainly focused on the immune response of adipose tissue. Their influence on macrophage function contributing to adipose tissue inflammation was discussed in the previous section (Table 2). In addition, Onodera et al. (2017) demonstrated that EPA increased the number and proportion of T regulatory cells in epididymal adipose tissue of db/db mice. This result was mediated by 5-HEPE, which is derived from EPA by 5-LOX (Onodera et al., 2017).

In addition to the immune response, other adipose tissue functions are regulated by ω-3 PUFA-derived bioactive metabolites.

**Effect of ω-3 PUFA-Derived Oxylipins on Lipogenesis and Lipolysis**

The imbalance of lipogenesis and lipolysis of adipose tissue can increase the risk of obesity-induced NASH, as evidenced by decreased macrophage infiltration with decreased expression of M1 macrophage markers and increased expression of M2 macrophage markers (Rius et al., 2014). Also, Han et al. (2019) demonstrated that MaR1 derived from DHA increased the M2 polarity of liver macrophages and then ameliorated NASH by activating RORα. RORα, as a nuclear receptor, in turn increased MaR1 production by transcriptional induction of 12-lipoxygenase expression (Han et al., 2019). These studies suggest that these specialized pro-resolving lipid mediators derived from ω-3 PUFA have therapeutic potential for NASH by promoting M2 polarization of liver macrophages.

**Effect of ω-3 PUFA-Derived Oxylipins on Non-alcoholic Steatohepatitis**

Non-alcoholic steatohepatitis is characterized by liver steatosis, inflammation, hepatocellular injury and different degrees of fibrosis and is the progressive form of NAFLD (Schuster et al., 2018). A recent study found RvD1 treatment mitigated lipid accumulation, inflammation and hepatic fibrosis in MCD-diet induced NASH mice. For the mechanism, RvD1 suppressed oxidative stress by activating nuclear factor E2-related factor 2 and ameliorated inflammation by inhibiting NF-κB and MAPK signaling pathways (Li et al., 2020). In addition, RvD1 had additional protective effects on calorie restrictive-improved NASH, as evidenced by decreased macrophage infiltration with decreased expression of M1 macrophage markers and increased expression of M2 macrophage markers (Rius et al., 2014). Also, Han et al. (2019) demonstrated that MaR1 derived from DHA increased the M2 polarity of liver macrophages and then ameliorated NASH by activating RORα. RORα, as a nuclear receptor, in turn increased MaR1 production by transcriptional induction of 12-lipoxygenase expression (Han et al., 2019). These studies suggest that these specialized pro-resolving lipid mediators derived from ω-3 PUFA have therapeutic potential for NASH by promoting M2 polarization of liver macrophages.
activated by cAMP (EPAC) (Hilgendorf et al., 2019). Because GPR120 can be activated by PDX, this research implies the complicated effects of ω-3 PUFA-derived bioactive lipids on adipogenesis. In addition, more studies are needed to demonstrate whether ω-3 derived bioactive lipids can affect the lipid storage and release function of adipose tissue in vivo.

**Effect of ω-3 PUFA-Derived Oxylipins on Endocrine Function of Adipose Tissue**

Adipose tissue, as an endocrine tissue, can affect other tissue functions by secreting cytokines. MaR1, 18-HEPE, 17-HDHA, RvD1, and PD1 could increase adiponectin level (Gonzalez-Periz et al., 2009; Hellmann et al., 2011; Rius et al., 2014; Martinez-Fernandez et al., 2017; Rodriguez-Echevarria et al., 2018). Adiponectin is an adipose-derived cytokine, one of the most abundant proteins in circulation (Wang et al., 2010). Because adiponectin is beneficial for diabetes, inflammation, and atherosclerosis (Achari and Jain, 2017), these bioactive lipids may affect metabolic disorders indirectly by promoting adiponectin secretion, which needs to be further explored.

**Effect of ω-3 PUFA-Derived Oxylipins on Brown and Beige Adipose Tissue**

Brown and beige adipocytes, as heat-producing cells, are considered to counteract metabolic diseases, including obesity and type 2 diabetes. Leiria et al. (2019) found that the 12-LOX biosynthetic pathway was activated in brown adipose tissue under cold exposure, which promoted the generation and release of 12-HEPE. Then, 12-HEPE exerted a glucose-shuttling effect on tissues to support thermogenesis (Leiria et al., 2019).

GPR120 is highly expressed in brown adipose tissue and significantly upregulated in beige adipose tissue induced by cold exposure. It was further found to mediate ω-3 PUFA-induced thermogenic gene expression in beige adipocytes by upregulating fibroblast growth factor 21 expression (Quesada-Lopez et al., 2016). However, the role of ω-3 PUFA metabolites in white adipose tissue browning remains unknown. GPR120 can be activated by PDX, but whether these ω-3 PUFA-derived bioactive lipids could regulate this process is worth studying.

Besides the direct effects on adipose tissue, ω-3 PUFA metabolites are reported to indirectly regulate adipose tissue function. GPR18, the receptor for RvD2, is widely expressed in hypothalamus and was decreased in level by HFD feeding in mice. In addition, the production of hypothalamic RvD2 was decreased in HFD-fed mice. When obese mice were treated with intra-cerebroventricular injection of RvD2, visceral fat was reduced, and hypothalamic leptin resistance was reversed (Pascoal et al., 2017).

**EFFECT OF ω-3 PUFA-DERIVED OXYLIPINS ON ATHEROSCLEROSIS**

Atherosclerosis causes ischemic heart disease, strokes, and peripheral vascular disease (Kobiyama and Ley, 2018). Metabolic syndrome is responsible for the initial disease and disease progression (Varghese et al., 2018). Endothelial-cell dysfunction is the initial step of atherosclerosis. Plaque is chronically built up with the assistance of macrophages differentiated from monocytes, smooth muscle cells and multiple chemokines and growth factors (Gimbrone and Garcia-Cardena, 2016). The metabolites derived from EPA or DHA, including RvE1, RvD2, MaR1, 18-HEPE, and 17,18-EEQ, have shown positive effects on anti-atherosclerosis (Table 2).

Systematic plasma lipidomic research has identified 18-HEPE as a central molecule derived from EPA. 18-HEPE is an RvE1 precursor, and knockout of the RvE1 receptor ERV-1 enhanced atherosclerosis and promoted changes in plaque composition in ApoE-/- mice. The mechanism study showed that ERV-1/ChemR23-/- macrophages enhanced oxidized low-density lipoprotein uptake and decreased phagocytosis (Laguna-Fernandez et al., 2018). RvE1 can ameliorate atherosclerosis (Salic et al., 2016). In addition, 18-HEPE and 17,18-EEQ ameliorated endothelial-cell activation and monocyte adhesion by inhibiting the TNFα-induced NF-κB pathway (Liu et al., 2018).

In the ApoE-/- mouse aorta, RvD2 and MaR1 levels are correlated negatively with vulnerability plaque index, which is decreased by HFD treatment. In addition, RvD2 and MaR1 administration suppressed atheroprogression. The protective effects of RvD2 and MaR1 on atherosclerosis were mediated by preventing the macrophage inflammatory response (Viola et al., 2016). RvD1 was decreased in vulnerable regions as compared with stable regions in human carotid atherosclerotic plaques. Additionally, its level was decreased in advanced versus early atherosclerotic lesion in western diet-fed mice deficient in low-density-lipoprotein receptor (Fredman et al., 2016). These studies suggest that several metabolites of EPA and DHA are beneficial for atherosclerosis. However, more in vivo and mechanistic studies are needed to better understand their effects on atherosclerosis.

**EFFECT OF n-3 DPA AND ITS DERIVATIVES ON METABOLIC DISORDERS**

n-3 DPA, an important ω-3 PUFA, is also a precursor of various docosanoids. Besides, it is an important intermediate in the conversion pathway of EPA and DHA (Figure 2; Drouin et al., 2019). n-3 DPA supplement significantly improved homeostasis model assessment of insulin resistance (HOMA-IR) in HFD fed mice, while DHA and EPA showed a minor effect (Guo et al., 2018). In human, n-3 DPA and its pro-resolving mediators have beneficial effects on cardiometabolic disease (Li et al., 2018). Moreover, It has been proved to be more potent than EPA in inducing the differentiation process in preadipocytes, and inhibits the pro-inflammatory signaling pathways (Murali et al., 2014). Although, it showed more beneficial effects on those metabolic disorders mentioned above than EPA and DHA, the functions of its metabolites are poorly studied.
n-3 DPA can be metabolized into PD₃DPA, RvD₃DPA, MaR₃DPA, hydroxylated derivatives from n-3 DPA, 13-serie Rvs etc. Several functional studies about n-3 DPA derivatives indicates their anti-inflammation function. A recent study found significant decreases in plasma RvD₃DPA concentrations in CVD patients and RvD₃DPA reduce leukocyte and platelet activation in peripheral blood from healthy volunteers as well as CVD patients. In addition, RvD₅DPA reduced aortic lesions in western diet-fed ApoE/- mice (Colas et al., 2018). PD₃DPA also found to play an important role in regulating macrophage resolution responses (Pistorius et al., 2018). PD₁₃DPA and RvD₅DPA were reported to decrease leukocyte–endothelial interaction and attenuate intestinal inflammation (Gobbetti et al., 2017). Although these n-3 DPA derivatives are identified as novel specialized proresolving lipid mediators, their effects on metabolic disorders, such as diabetes, NAFLD, obesity and atherosclerosis are still largely unknown.

### EFFECT OF ALA AND ITS DERIVATIVES ON METABOLIC DISORDERS

In addition to partially converted into EPA, n-3 DPA and DHA (with low conversion rate to DHA in human) (de Lorgeril and Salen, 2004; Stark et al., 2008, 2016), the effects of oxylipins derived from ALA by LOX and CYP have also gained attention. Recently, a clinical research showed that 9-hydroxy-octadecatrienoic acid (9-HOTRE) combined with 7,17dihydro-dipicolinic acid (7,17-DHDPA), 14,15-dihydroxy-5,8,11-eicosatrienoic acid (14,15-DIHETRE) and free adrenic acid is a biomarker to predict improvement in hepatic collagen content in NASH patients (Caussy et al., 2020). Moreover, 13-(S)-HOTRE showed anti-inflammatory effects by inactivating (S)-HOTRE and 13-(S)-hydroxyoctadecatrienoic acid (13-(S)-HPOTRE) [13-(S)-HOTRE] showed anti-inflammatory effects by inactivating NLRP3 inflammasome complex in macrophages, which indicates that they may play protective roles in metabolic disorders (Kumar et al., 2016). However, the studies about the effects of ALA derivatives on metabolic are limited, especially the in vivo study.

### CONCLUSION

Although we have fewer studies of the biofunctions of ω-3 PUFA-derived bioactive lipids than ARA metabolites, the former have been increasingly emphasized recently, especially for metabolic disorders (Table 2). Most of the functional studies focused on their anti-inflammatory effects. These metabolites can be more effective against inflammation than the precursors per se. Because PUFAs are vulnerable to lipid peroxidation, ω-3 PUFA supplement can lead to increased lipid peroxidation products, which may limits their clinical applications (Zaloga, 2021). It is important to increase their anti-inflammatory efficiency and decrease the dosage. Therefore, studying the function ω-3 PUFA metabolites may help us to find novel lipid mediators to treat metabolic disorders better than dietary supplement of EPA and DHA. Moreover, the anti-inflammatory efficiency of these metabolites should be further compared to provide more information for the future clinical applications.

In addition, several studies revealed the direct effects of ω-3 PUFA-derived oxylipins on pancreatic β cells, hepatocytes, adipocytes, skeletal muscle cells and endothelial cells. These bioactive lipids may have potential effects other than anti-inflammatory effects, which needs more exploration. Metabolites derived from ω-3 PUFAs are numerous, with attention to RvEs, RvDs, and PDs. Other metabolites such as EEQs, EDPs, HEPEs, and n-3 DPA derivatives need more mechanistic studies. In addition, the explorations of the biofunctions of ω-3 PUFA-derived bioactive metabolites, including their effects on cellular function, tissue micro-environment and interactions among metabolic tissues, are important for understanding their roles in energy metabolic disorders and related diseases. We also need more studies to identify their receptors and elucidate the downstream signaling pathway, which may provide potential therapeutic strategies for metabolic disorders.

In animal studies, the age, sex, and background of animals are well controlled. However, plasma and tissue levels of EPA and DHA and their metabolites in human can be altered by age, sex and disease status (Calder, 2020a), which indicates the complexity of clinical application of EPA and DHA. The genetic variants in the specialized pro-resolving mediator response also need to be considered when exploring the therapeutic effects of EPA and DHA clinically. Thus, the individualized treatment regimens of clinical applications of ω-3 PUFAs may achieve better effects on metabolic disorders. Moreover, according to a recent clinical trial, high-dose ω-3 PUFA supplement failed to increased RvD1 levels in diabetic patients, indicating the importance to study the disturbance of ω-3 PUFA metabolism in some disease status.

### AUTHOR CONTRIBUTIONS

JD and YS contributed to the drafting, figure composition, subsequent edits, and final composition of the manuscript. XZ provided the comments and corrections. CW contributed to the concept and design, drafting of the manuscript, and guarantor of the manuscript. All authors have read and approved the final manuscript.

### FUNDING

This work was supported by the National Natural Science Foundation of China (81822006 and 81770836) and the Natural Science Foundation of Tianjin (20JCYBJC01120).
REFERENCES
Achari, A. E., and Jain, S. K. (2017). Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int. J. Mol. Sci. 18:1321. doi: 10.3390/ijms18061321
Ahmed, M. (2015). Non-alcoholic fatty liver disease in 2015. World J. Hepatol. 7, 1450–1459. doi: 10.4026/wjh.v7.i11.1450
Bathina, S., and Das, U. N. (2021). Resolvin D1 decreases severity of streptozotocin-induced Type 1 diabetes mellitus by enhancing BDNF levels, reducing oxidative stress, and suppressing inflammation. Int. J. Mol. Sci. 22:1516. doi: 10.3390/ijms22041516
Bathina, S., Gundala, N. K. V., Rhenghachar, P., Polavarapu, S., Hari, A. D., Sadananda, M., et al. (2020). Resolvin D1 Ameliorates Nicotinamide-streptozotocin-induced Type 2 Diabetes mellitus by its anti-inflammatory action and modulating PI3K/Akt/mTOR pathway in the brain. Arch. Med. Res. 51, 492–503. doi: 10.1016/j.arcmed.2020.05.002
Bi, X., Li, F., Liu, S., Jin, Y., Zhang, X., Yang, T., et al. (2017). omega-3 polyunsaturated fatty acids ameliorate type 1 diabetes and autoimmune. J. Clin. Invest. 127, 1757–1771. doi: 10.1172/JCI87388
Calder, P. C. (2020a). Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving mediators: concentrations in humans and the effects of age, sex, disease and increased omega-3 fatty acid intake. Biochimie 178, 105–123. doi: 10.1016/j.biochem.2020.08.015
Calder, P. C. (2020b). Eicosanoids. Essays Biochem. 64, 423–441. doi: 10.1042/ EBC20190083
Caliguri, S. P., Love, K., Wintor, T., Gauthier, J., Taylor, C. G., Blydt-Hansen, T., et al. (2013). Dietary linoleic acid and alpha-linolenic acid differentially affect renal oxylipins and phospholipid fatty acids in diet-induced obese rats. J. Nutr. 143, 1421–1427. doi: 10.3945/jn.113.177360
Causso, C., Chuang, J. C., Billin, A., Hu, T., Wang, Y., Subramanian, G. M., et al. (2020). Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis. Ther. Adv. Gastroenterol. 13:1756284820923904. doi: 10.1177/1756284820923904
Chiang, N., Dalli, J., Colas, R. A., and Serhan, C. N. (2015). Identification of resolvin D2 receptor mediating resolution of infections and organ protection. J. Exp. Med. 212, 1203–1217. doi: 10.1084/jem.20150025
Chiang, N., Libreros, S., Norris, P. C., de la Rosa, X., and Serhan, C. N. (2019). Identification of resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese diabetic mice. Prostaglandins Leukot Essent Fatty Acids 129, 620–636. doi: 10.1016/j.prostaglandins.2019.106351
Chiang, N., Libreros, S., Norris, P. C., de la Rosa, X., and Serhan, C. N. (2019). A maresin 1/RORalpha/12-lipoxygenase autoregulatory circuit prevents inflammation and progression of nonalcoholic steatohepatitis. J. Clin. Invest. 129, 1684–1692. doi: 10.1172/JCI124219
He, J., Wang, C., Zhu, Y., and Ai, D. (2016). Soluble epoxide hydrolase: a potential target for metabolic diseases. J. Diabetes 8, 305–313. doi: 10.1111/1753-0407.12358
Hellyn, J., Tang, Y., Kosuri, M., Bhattachar, A., and Spite, M. (2011). Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J. 25, 2399–2407. doi: 10.1096/fj.10-174657
Hilgendorf, K. L., Johnson, C. T., Mezger, A., Rice, S. L., Norris, A. M., Demeter, J., et al. (2019). Omega-3 fatty acids activate ciliary FFA4 to control adipogenesis. Cell 179, 1289.e21–1305.e21. doi: 10.1016/j.cell.2019.11.005
Hu, J., Dziomba, S., Lin, J., Bibi, L. S., Zukunft, S., de Mos, J., et al. (2017). Inhibition of soluble epoxide hydrolase prevents diabetic retinopathy. Nature 552, 248–252. doi: 10.1038/nature25013
Hwang, H. J., Jung, T. W., Kim, J. Y., Ahn, S. H., Shin, J. W., Kim, H. C., Park, E. S., Abd El-Aty, M., et al. (2013). Dietary linoleic acid and alpha-linolenic acid differentially affect metabolic and inflammatory biomarkers in Type 2 diabetes mellitus patients. Nutrients 5, 1320–1345. doi: 10.3390/ nu5051319
Jordão Candido, C., Silva Figueiredo, P., Del Ciampo Silva, R., Candeloro Portugal, L., Augusto Dos Santos Jaques, J., Alves de Almeida, J., et al. (2019). Protective effect of alpha-linolenic acid on non-alcoholic hepatic steatosis and interleukin-6 and -10 in wistar rats. Nutrients 12:9. doi: 10.3390/nu12090809
Jung, T. W., Ahn, S. H., Shin, J. W., Kim, H. C., Park, E. S., Abd El-Aty, A. M., et al. (2019). Proteomic DX ameliorates palmitate-induced hepatic insulin resistance through AMPK/SIRT1-mediated modulation of hepatic resistance and lipotoxicity in a feeding and exercise intervention. PLoS One 14, e0219421. doi: 10.1371/journal.pone.0219421
Jung, T. W., Chung, Y. H., Kim, H. C., Abd El-Aty, A. M., and Jeong, J. H. (2018a). Protective DX attenuates LPS-induced inflammation and insulin resistance in adipocytes via AMPK-mediated suppression of the NF-kappaB pathway. Am. J. Physiol. Endocrinol. Metab. 315, E543–E551. doi: 10.1152/ajpendo.00408. 2017
Kumar, N., Gupta, G., Anilkumar, K., Fatima, N., Karnati, R., Reddy, G. V., et al. (2014). Adipose tissue and adipocyte dysregulation. Frontiers in Physiology | www.frontiersin.org 11

Kuda, O. (2017). Bioactive metabolites of docosahexaenoic acid. Nutrition 768.e7–783.e7. doi: 10.1016/j.nute.2016.11.007

Kraish, S., Haskel, E., Sidi, O., and Kurovski, V. (2016). 15-Lipoxygenase metabolites of α-linolenic acid, [13-(S)-HPOTrE and 13-(S)-HOTrE], mediate anti-inflammatory effects by inactivating NLRP3 inflammasome. Sci. Rep. 6:31649. doi: 10.1038/srep31649

Laiglesia, L. M., Lorente-Cebrian, S., Lopez-Yoldi, M., Lanas, R., Sainz, N., Martinez, J. A., et al. (2018a). Maresin 1 inhibits TNF-alpha-induced lipolysis and autophagy in 3T3-L1 adipocytes. J. Cell. Physiol. 233, 2238–2246. doi: 10.1002/jcp.26096

Laiglesia, L. M., Lorente-Cebrian, S., Martinez-Fernandez, L., Sainz, N., Prieto-Hontoria, P. L., and Martinez-Fernandez, L. (2018b). Maresin 1 improves insulin sensitivity: focus on the regulation of mitochondrial and endoplasmic reticulum stress. Nutrients 10:350. doi: 10.3390/nu10030350

Li, J., Deng, X., Bai, T., Wang, S., Jiang, Q., and Xu, K. (2020). Resolvin D1 mitigates non-alcoholic steatohepatitis by suppressing the TLRL4-MyD88-mediated NF-kappaB and MAPK pathways and activating the Nrfl2 pathway in mice. Int. Immunopharmacol. 88:106961. doi: 10.1016/j.intimp.2020.106961

Li, K., Sinclair, A. J., Zhao, F., and Li, D. (2018). Uncommon fatty acids and cardiometabolic health. Nutrients 10:1559. doi: 10.3390/nu10101559

Liu, Y., Fang, X., Zhang, X., Huang, J., He, J., Peng, L., et al. (2018). Metabolic profiling of murine plasma reveals eicosapentaenoic acid metabolites protecting against endothelial activation and atherosclerosis. Br. J. Pharmacol. 175, 1190–1204. doi: 10.1111/bjp.13971

Lopez-Vicario, C., Alcaraz-Quiles, J., Garcia-Alonso, V., Rius, B., Hwang, S. H., Titos, E., et al. (2015). Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: role for omega-3 eicosapentaenoic acid. Prog. Nutr. Sci. U.S.A. 112, 536–541. doi: 10.1073/pnas.1422990112

Mäisto, R., Trotta, M. C., Petrillo, F., Izzo, S., Cuomo, G., Alfano, R., et al. (2020). Resolvin D1 modulates the intracellular VEGF-Related miRNAs of retinal photoreceptors challenged with high glucose. Front. Pharmacol. 11:235. doi: 10.3389/fphar.2020.00235

Martinez-Fernandez, L., Gonzalez-Muniesa, P., Laiglesia, L. M., Sainz, N., Prieto-Hontoria, P. L., Escote, X., et al. (2017). Maresin 1 improves insulin sensitivity and attenuates adipose tissue inflammation in ob/ob and diet-induced obese mice. FASEB J. 31, 2135–2145. doi: 10.1096/fj.201600859R

Martinez-Fernandez, L., Gonzalez-Muniesa, P., Sainz, N., Escote, X., Martinez, J. A., Arbones-Mainar, J. M., et al. (2020). Maresin 1 regulates insulin signaling in human adipocytes as well as in adipose tissue and muscle of lean and obese mice. J. Physiol. Biochem. 77, 167–173. doi: 10.1111/jphb.12030

Matsuoka, T., and Shimano, H. (2011). Molecular mechanisms involved in hepatic steatosis and insulin resistance. J. Diabetes Invest. 2, 170–175. doi: 10.1111/j.1754-2227.2010.00111.x

Meijerink, J., Balvers, M., and Witkamp, R. N. - (2013). Acyl amines of docosahexaenoic acid and other n-3 polysaturated fatty acids - from fishy endocannabinoids to potential leads. Br. J. Pharmacol. 169, 772–783. doi: 10.1111/j.1476-5381.2012.01203.x

Murali, G., Desouza, C. V., Clevenger, E. M., Ramalingam, R., and Saraswathi, V. (2014). Differential effects of eicosapentaenoic acid and docosahexaenoic acid in promoting the differentiation of 3T3-L1 preadipocytes. Prostaglandins Leukot Essent Fatty Acids 90, 13–21. doi: 10.1016/j.plfa.2013.10.002

Neuhofer, A., Zeyda, M., Mascher, D., Itariu, B. K., Murano, I., Leitner, L., et al. (2013). Impaired local production of proresolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation. Diabetes 62, 1945–1956. doi: 10.2337/db12-0828

Neuman, J. C., Schaid, M. D., Brill, A. L., Fenske, R. J., Kibbe, C. R., Fontaine, D. A., et al. (2017). Enriching islet phospholipids with eicosapentaenoic acid reduces Prostaglandin E2 signaling and enhances diabetic beta-cell function. Diabetes 66, 1572–1585. doi: 10.2337/db16-1362

Onodera, T., Fukuhara, A., Shin, J., Hayakawa, T., Otsuki, M., and Shimomura, I. (2017). Eicosapentaenoic acid and 5-HEPE enhance macrophase-mediated Treg induction in mice. Sci. Rep. 7:4560. doi: 10.1038/s41598-017-04474-2

Pal, A., Al-Shaer, A. E., Guesdon, W., Torres, M. J., Armstrong, M., Quinn, K., et al. (2020). Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner. FASEB J. 34, 10460–10465. doi: 10.1096/fj.202000830R

Park, H. G., Park, W. J., Kohlappali, S. K., and Brenna, J. T. (2015). The fatty acid desaturase 2 (FADS2) gene product catalyzes Δ4 desaturation to yield n-3 docosahexaenoic acid and n-6 docosahexaenoic acid in human cells. FASEB J. 29, 3911–3919. doi: 10.1096/fj.15-271783

Pascoal, L. B., Bombassaro, B., Ramalho, A. F., Coope, A., Moura, R. F., Correa-Silva, F., et al. (2017). Resolvin RvD2 reduces hypothalamic inflammation and rescues mice from diet-induced obesity. J. Neuroinflammation 14:5. doi: 10.1186/s12974-016-0777-2

Pistorius, K., Souza, P. R., De Matteis, R., Austin-Williams, S., Primdahl, K. G., Vik, A., et al. (2018). PD(n-3 DPA) pathway regulates human monocyte differentiation and macrophage function. Cell Chem. Biol. 25, 749.e9–760.e9. doi: 10.1016/j.chembiol.2018.04.017

Poreba, M., Mostowik, M., Sznarski, A., Golebiowska-Wiatrak, R., Malinowski, K., et al. (2017). The specialized proresolving lipid receptor proresolving receptors. Proc. Natl. Acad. Sci. U.S.A. 114, 11249–11254. doi: 10.1073/pnas.1716131112

Rius, B., Duran-Guell, M., Flores-Costa, R., Lopez-Vicario, C., Lopategi, A., Alcaraz-Quiles, J., et al. (2017). The specialized proresolving lipid mediator maresin 1 protects hepatocytes from lipotoxic and hypoxia-induced...
endoplasmic reticulum stress. FASEB J. 31, 5384–5398. doi: 10.1096/fj.20170394R
Rius, B., Titos, E., Moran-Salvador, E., Lopez-Vicario, C., Garcia-Alonso, V., Gonzalez-Periz, A., et al. (2014). Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohapatitis. FASEB J. 28, 836–848. doi: 10.1096/fj.13-235614
Rodriguez-Echevarria, R., Macias-Barragan, J., Parra-Vargas, M., Davila-Rodriguez, J. R., Amezcu-Galvez, E., and Armandier- Borunda, J. (2018). Diet switch and omega-3 hydroxy-fatty acids display differential hepatoprotective effects in an obesity/nonalcoholic fatty liver disease model in mice. World J. Gastroenterol. 24, 461–474. doi: 10.3780/wjg.v24.14.461
Rosen, E. D., and Spiegelman, B. M. (2014). What we talk about when we talk about fat. Cell 156, 20–44. doi: 10.1016/j.cell.2013.12.012
Saito, M., Ishida, N., Yamada, H., Ibi, M., and Hirose, M. (2020). 8-HEPE-concentrated materials from pacific krill improve plasma cholesterol levels and hepatic steatosis in high cholesterol diet-fed low-density lipoprotein (LDL) receptor-deficient mice. Bioll. Pharm. Bull. 43, 919–924. doi: 10.1248/bpb.b20-00162
Saleh-Ghadimi, S., Kheirouri, S., Maleki, V., Jafari-Vayghan, H., and Alizadeh, M. (2020). Endocannabinoid system and cardiometabolic risk factors: a comprehensive systematic review insight into the mechanistic effects of omega-3 fatty acids. Life Sci. 250:117556. doi: 10.1016/j.lfs.2020.117556
Salic, K., Morrison, M. C., Verschuren, L., Wielinga, P. Y., Wu, L., Kleemann, R., et al. (2016). Resolv E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. Atherosclerosis 250, 158–165. doi: 10.1016/j.atherosclerosis.2016.05.001
Sawada, T., Tsubata, H., Hashimoto, N., Takabe, M., Miyata, T., Aoki, K., et al. (2016). Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial. Cardiovasc. Diabetol. 15:121. doi: 10.1186/s12933-016-0437-y
Schmitz, G., and Ecker, J. (2008). The opposing effects of n-3 and n-6 fatty acids. Prog. Lipid Res. 47, 147–155. doi: 10.1016/j.plipres.2007.12.004
Schuster, S., Cabrera, D., Arrese, M., and Feldstein, A. E. (2018). Triggering and resolution of inflammation in NASH. Nat. Rev. Gastroenterol Hepatol. 20, 664–669. doi: 10.1038/nrgastro.2017.3549
Wong, C. Y., Yiu, K. H., Li, S. W., Lee, S., Tam, S., Lau, C. P., et al. (2010). Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus. Diabet. Med. 27, 54–60. doi: 10.1111/j.1464-5491.2009.02869.x
Xu, P., Zhai, Y., and Wang, J. (2010). Cytokines in the progression of obesity and glucose intolerance. Sci. Rep. 56, 2261–2267. doi: 10.1080/10408398.2013.823549
Ye, C., Duan, J., Zhang, X., Yao, L., Song, Y., Wang, G., et al. (2020). Cold-induced PUFA Metabolites in Metabolic Disorders.